Education & Support
Educational Resources
Educational resources
Find resources for both health care professionals and patients.
Patient education tools
Back to top
AstraZeneca oncology Web sites
ARIMIDEX.com: information, resources, and support for women taking ARIMIDEX
ARIMIDEX for international health care professionals: an information resource for international health care professionals with an interest in breast cancer treatment
-
AstraZeneca Oncology Portal: AstraZenecaOncology.com is a clinical resource offering in-depth information about AstraZeneca's oncology products and research direction including information about emerging oncology compounds, clinical trials, slide kits, and Mechanisms of Action, as well as product information. The site highlights AstraZeneca's heritage within oncology as well as our commitment to the future of oncology.
Celebration Chain: a place to honor women who are facing or have faced breast cancer
FASLODEX.com: information, resources, and support for women taking FASLODEX
FASLODEX for health care professionals: an information resource for health care professionals with an interest in the treatment of metastatic breast cancer
Hormonal Aspects of Breast Cancer Lecture Series: Web-based lectures led by nationally recognized breast cancer experts on the hormonal treatment of breast cancer patients
In Your Corner : a patient support program for women on hormonal treatment for breast cancer
Leading Ladies of Breast Cancer: Breast cancer patients share their stories of active survivorship
Back to top
Other professional resources
- The organizations and Web sites listed below may be of interest to oncology professionals.
- The following list of resources is provided merely as a convenience. AstraZeneca takes no responsibility for the content of, or services provided by, these resources, and makes no representations as to the accuracy or completeness of any information provided. AstraZeneca shall have no liability for any damages or injuries of any kind arising from the information provided.
- American Academy of Family Physicians
11400 Tomahawk Creek Parkway
Leawood, KS 66211-2672
Phone: 800-274-2237
www.aafp.org
- American Academy of Hospice and Palliative Medicine
4700 W. Lake Ave.
Glenview, IL 60025-1485
Phone: 847-375-4712
E-mail: info@aahpm.org
www.aahpm.org
- American Cancer Society
1180 Avenue of the Americas
New York, NY 10036
Phone: 1-800-227-2345
www.cancer.org
- American College of Obstetricians and Gynecologists
409 12th Street, SW
PO Box 96920
Washington, DC 20090
Phone: 202-638-5577
www.acog.com
- American Medical Women's Association
100 N. 20th Street, 4th Floor
Philadelphia, PA 19103
Phone: 215-320-3716
www.amwa-doc.org
- American Nurses Association
8515 Georgia Avenue
Suite 400
Silver Spring, MD 20910
Phone: 301-628-5000 or 800-274-4ANA (4262)
Fax: 301-628-5001
www.nursingworld.org
- American Pain Foundation
201 N. Charles Street, Suite 710
Baltimore, MD 21201-4111
Phone: 888-615-PAIN (7246)
E-mail: info@painfoundation.org
www.painfoundation.org/default.asp
- American Society of Clinical Oncology
2318 Mill Road, Suite 800
Alexandria, VA 22314
Phone: 703-299-0150
www.asco.org
- CancerCare, Inc.
275 Seventh Avenue
New York, NY 10001
Phone: 212-721-8400 or 800-813-4673
www.cancercare.org
- Centers for Disease Control and Prevention
Office of Program and Policy Information
National Center for Chronic Disease Prevention and Health Promotion
Division of Cancer Prevention and Control
4770 Bulford Highway, NE
Mail Stop K64
Atlanta, GA 30341-3717
Phone: 800-CDC-INFO
Fax: 770-488-4760
E-mail: cdcinfo@cdc.gov
www.cdc.gov/cancer/nbccedp
- End-of-Life Nursing Education Consortium (ELNEC) Project
American Association of Colleges of Nursing
One Dupont Circle, NW, Suite 530
Washington, DC 20036
Phone: 202-463-6930
Fax: 202-785-8320
www.aacn.nche.edu/elnec
- National Cancer Institute
NCI Public Inquiries Office
6116 Executive Boulevard
Room 3036A
Bethesda, MD 20892-8322
Phone: 800-4-CANCER
www.cancer.gov
- National Medical Association
1012 10th Street, NW
Washington, DC 20001
Phone: 202-347-1895
Fax: 202-898-2510
www.nmanet.org
- Oncology Nursing Society
125 Enterprise Drive
Pittsburgh, PA 15275
Phone: 866-257-4ONS or 412-859-6100
Fax: 877-369-5497 (toll-free) or 412-859-6162
E-mail: customer.service@ons.org
www.ons.org
- Prevent Cancer Foundation
1600 Duke Street, Suite 110
Alexandria, VA 22314
Phone: 703-836-4412
www.preventcancer.org
Back to top
Other patient resources
- Patients currently undergoing treatment for breast cancer may find the following consumer sites of interest and helpful as their course of treatment proceeds.
- The following list of resources is provided merely as a convenience. AstraZeneca takes no responsibility for the content of, or services provided by, these resources, and makes no representations as to the accuracy or completeness of any information provided. AstraZeneca shall have no liability for any damages or injuries of any kind arising from the information provided.
- American Cancer Society
1180 Avenue of the Americas
New York, NY 10036
Phone: 800-227-2345
or
1599 Clifton Road, NE
Atlanta, GA 30329
www.cancer.org
- BreastCancer.org
7 East Lancaster Ave.
3rd Floor
Ardmore, PA 19003
www.breastcancer.org
- Breast Cancer Network of Strength
212 W. Van Buren, Tenth Floor
Chicago, IL 60607-3903
Phone: 312-986-8338
Fax: 312-294-8598
www.networkofstrength.org
- CancerCare
275 Seventh Avenue
New York, NY 10001
Phone: 212-721-8400 or 800-813-4673
www.cancercare.org
- Centers for Disease Control and Prevention
Program and Policy Information Division of Cancer Prevention and Control
4770 Bulford Highway, NE
Mail Stop K-64
Atlanta, GA 30341-3717
Phone: 800-CDC-INFO
E-mail: cdcinfo@cdc.gov
www.cdc.gov/cancer/nbccedp
- National Cancer Institute
NCI Public Inquiries Office
6116 Executive Boulevard
Room 3036
Bethesda, MD 20892-8322
Phone: 800-4-CANCER
www.cancer.gov
- National Alliance of Breast Cancer Organizations (NABCO)
9 East 37th Street
New York, NY 10016
Phone: 888-80-NABCO
www.nabco.org
- OncoLink Editorial Board
Abramson Cancer Center of the University of Pennsylvania
3400 Spruce Street, 2 Donner
Philadelphia, PA 19104-4283
E-mail: webmaster@oncolink.com
Phone: 800-622-2838 or 202-296-7477
http://www.oncolink.upenn.edu
- Oncology Nursing Society
125 Enterprise Drive
Pittsburgh, PA 15275
Phone: 866-257-4ONS or 412-859-6100
Fax: 877-369-5497 (toll-free) or 412-859-6162
E-mail: customer.service@ons.org
www.ons.org
- Prevent Cancer Foundation
1600 Duke Street, Suite 110
Alexandria, VA 22314
Phone: 703-836-4412
www.preventcancer.org
- Susan G. Komen for the Cure
5005 LBJ Freeway, Suite 250
Dallas, TX 75244
Phone: 972-855-1600 or 1-877-GO-KOMEN
www.komen.org
- The National Breast Cancer Coalition
1101 17th Street, NW, Suite 1300
Washington, DC 20036
Phone: 800-622-2838 or 202-296-7477
Fax: 202-265-6854
www.stopbreastcancer.org
Back to top
Request to have an AstraZeneca representative contact you with more information about Arimidex
Request a Rep
Arimidex is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Arimidex is indicated for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Arimidex.
Important Safety Information About Arimidex
- Arimidex is only for postmenopausal women. Arimidex can cause fetal harm when administered to a pregnant woman. Before starting treatment with Arimidex, pregnancy must be excluded (see warnings section of full Prescribing Information)
- In women with preexisting ischemic heart disease 465/6186 (7.5%), an increased incidence of ischemic cardiovascular events occurred with Arimidex (17%) vs tamoxifen (10%). In this patient population, angina pectoris was reported in 25/216 (11.6%) vs 13/249 (5.2%) and myocardial infarction was reported in 2/216 (0.9%) vs 8/249 (3.2%) patients receiving Arimidex and tamoxifen, respectively
- Compared to baseline, Arimidex showed a mean decrease in both lumbar spine and total hip bone mineral density. Tamoxifen showed a mean increase in these measurements. Nine percent of patients receiving Arimidex had an elevated serum cholesterol vs 3.5% of patients receiving tamoxifen
- Common side effects seen with Arimidex vs tamoxifen in the early breast cancer trial after 5 years of treatment include hot flashes (36% vs 41%), joint disorders (including arthritis, arthrosis, arthralgia) (36% vs 29%), asthenia (19% vs 18%), mood disturbances (19% vs 18%), pain (17% vs 16%), pharyngitis (14% vs 14%), nausea and vomiting (13% vs 12%), rash (11% vs 13%), depression (13% vs 12%), hypertension (13% vs 11%), osteoporosis (11% vs 7%), peripheral edema (10% vs 11%), lymphedema (10% vs 11%), back pain (10% vs 10%), insomnia (10% vs 9%), and headache (10% vs 8%). Fractures, including fractures of the spine, hip, and wrist, occurred more often with Arimidex vs tamoxifen (10% vs 7%)
- In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking Arimidex included hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis, and peripheral edema. Joint pain/stiffness has been reported in association with the use of Arimidex
- Clinical and pharmacokinetic results suggest that tamoxifen should not be administered with Arimidex. Estrogen-containing therapies should not be used with Arimidex as they may diminish its pharmacologic action
Please click here for full Prescribing Information.
Faslodex is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Important Safety Information About Faslodex
- Faslodex is only for postmenopausal women. Faslodex can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while receiving Faslodex. (See contraindications and warnings sections of full Prescribing Information)
- Because Faslodex is administered intramuscularly, it should not be used in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants
- In clinical trials, the most commonly reported adverse effects seen with Faslodex, regardless of the investigator's assessment of causality, were gastrointestinal symptoms (nausea 26.0%, vomiting 13.0%, constipation 12.5%, diarrhea 12.3%, abdominal pain 11.8%), headache 15.4%, back pain 14.4%, hot flashes 17.7%, and pharyngitis 16.1%. Injection site reactions with mild, transient pain and inflammation were reported in 7% of patients (1% of treatments) given a single 5 mL injection and 27% of patients (4.6% of treatments) given 2 x 2.5 mL injections of Faslodex
Please click here for full Prescribing Information.